2024年11月14日,中国国家医保局正式公布了《国家基本医疗保险、工伤保险和生育保险药品目录(2026年)》及《商业健康保险创新药品目录(2026年)》1。此次调整旨在减轻患者负担并推动更多创新药触达患者1。据统计,至少有18款罕见病药物被纳入新版国家医保目录,涉及13种罕见病;另有7种创新药被纳入商保创新药目录,涉及7种罕见病1。
在重点病种方面,血友病有4款新药纳入医保,重症肌无力有3款新药纳入医保1。具体案例中,血友病药物包括罗氏艾美赛珠单抗、赛诺菲芬妥司兰钠、辉瑞马塔西单抗、贝捷泰波米泰酶α等1;重症肌无力药物包括强生尼卡利单抗、优时比罗泽利昔珠单抗、再鼎艾加莫德等1。其中,尼卡利单抗是首次纳入国家医保目录;艾加莫德成为唯一两种给药方式均被纳入的重症肌无力靶向生物制剂1。
从企业分布来看,跨国药企产品占据主导,但中国本土创新药企在罕见病领域的自主研发力量也在崛起1。在新版医保目录的18款罕见病新药中,11款由跨国药企研发;在商保目录的7款中有5款为跨国药企研发1。与此同时,北京天广实、贝捷泰、朗来科技、正大天晴、华东医药、信致医药等多家中国药企的创新药入选1。
On November 14, 2024, China’s National Healthcare Security Administration officially released the National Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance Drug Catalogue (2026) alongside the Commercial Health Insurance Innovative Drug Catalogue (2026) 1. The updated national medical insurance catalogue includes at least 18 innovative drugs for rare diseases, addressing 13 specific conditions, while the commercial insurance catalogue incorporates seven new treatments covering seven distinct rare diseases 1. This adjustment aims to alleviate patient financial burdens and enhance accessibility to cutting-edge therapies 1.
Multinational pharmaceutical companies dominate the additions, with 11 of the 18 rare disease drugs in the national medical insurance catalogue and five of the seven entries in the commercial catalogue developed by global firms 1. Significant progress has been made for hemophilia patients, as four new drugs—including Roche’s Emicizumab, Sanofi’s Fitusiran sodium, Pfizer’s Marstacimab, and Beijing JieTai’s Bosentan alfa—were added to the medical insurance list 1. In the realm of myasthenia gravis, three new therapies were included: Johnson & Johnson’s Nicalizumab, UCB’s Rozelimab, and Zai Lab’s Efgartigimod 1. Notably, Nicalizumab enters the national medical insurance catalogue for the first time, while Efgartigimod becomes the only targeted biologic for myasthenia gravis with both administration methods covered 1.
Despite the prevalence of multinational products, domestic Chinese innovators are increasingly contributing to the rare disease landscape 1. Companies such as Beijing TianGuangShi, BeJieTai, LangLai Tech, Chia Tai Qing, Huadong Medicine, and XinZhi Pharma have successfully had their innovative drugs selected for the catalogues 1. These local advancements reflect a growing self-reliance in research and development within the sector, complementing the broader strategy to ensure more innovative medications reach patients 1.
评论
还没有评论,欢迎留下第一条。